■原著
切除不能進行再発胃癌に対するS-1＋シスプラチン療法の有害事象対策と外来化学療法
前島 顕太郎1, 2, 谷合 信彦2, 吉田 寛3
1蓮田病院外科
2日本医科大学武蔵小杉病院消化器外科
3日本医科大学付属病院消化器外科
Measures for Adverse Events and Outpatient Chemotherapy of S-1+Cisplatin for Unresectable Progressive Recurrent Gastric Cancer
Kentaro Maejima1, 2, Nobuhiko Taniai2 and Hiroshi Yoshida3
1)Department of Surgery, Hasuda Hospital
2)Department of Surgery, Nippon Medical School Musashi Kosugi Hospital
3)Department of Surgery, Nippon Medical School Hospital
Although S-1+cisplatin therapy is used as first-line therapy for unresectable progressive/recurrent gastric cancer, the incidence of adverse events is not low. Renal dysfunction, especially, is an important side effect of dose-limiting toxicity and requires caution. Conversely, outpatient chemotherapy is becoming popular nationwide, but at the time of cisplatin administration, it is burdensome for patients to be infused for hospitalization to prevent renal dysfunction. It is possible that there is no difference between the incidence of renal dysfunction in patients to whom cisplatin is administered during hospitalization and that in outpatients treated with a short hydration regimen. Furthermore, currently, because of the increase in the infusion speed and use of magnesium, data on renal dysfunction associated with cisplatin administration in outpatient settings have not been reported. Here we report a case of the onset of renal dysfunction.
日医大医会誌 2019; 15(3), 128-133
Key words
cisplatin, renal dysfunction, outpatient chemotherapy
Correspondence to
Kentaro Maejima, Department of Surgery, Hasuda Hospital, 1662-1 Negane, Hasuda-shi, Saitama 349-0131, Japan
E-mail：ken3363-attacker@nms.ac.jp
受付：2019年3月8日 受理：2019年5月2日 |
全文PDF